Growth Metrics

United Therapeutics (UTHR) Gains from Sales and Divestitures (2018 - 2020)

United Therapeutics (UTHR) has disclosed Gains from Sales and Divestitures for 3 consecutive years, with $104818.0 as the latest value for Q1 2020.

  • Quarterly Gains from Sales and Divestitures rose 127.73% to $104818.0 in Q1 2020 from the year-ago period, while the trailing twelve-month figure was $104818.0 through Mar 2020, up 127.73% year-over-year, with the annual reading at $74324.0 for FY2019, 290.13% up from the prior year.
  • Gains from Sales and Divestitures hit $104818.0 in Q1 2020 for United Therapeutics, up from $74324.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $104818.0 in Q1 2020 to a low of $17820.0 in Q2 2018.
  • Historically, Gains from Sales and Divestitures has averaged $51762.5 across 3 years, with a median of $55192.0 in 2019.
  • Biggest five-year swings in Gains from Sales and Divestitures: skyrocketed 290.13% in 2019 and later soared 127.73% in 2020.
  • Year by year, Gains from Sales and Divestitures stood at $19051.0 in 2018, then surged by 290.13% to $74324.0 in 2019, then surged by 41.03% to $104818.0 in 2020.
  • Business Quant data shows Gains from Sales and Divestitures for UTHR at $104818.0 in Q1 2020, $74324.0 in Q4 2019, and $69761.0 in Q3 2019.